InsidersTradesSigma
Total declarations
Company
▲ Purchases (7 ops.)
▼ Sales (0 ops.)
Explore the full record of transactions filed by Mickle Travis C, Chairman & CEO. Director active across 1 companies, notably Kempharm, INC. Cumulatively, 9 filings have been recorded. Total volume traded: €152k. The latest transaction was filed on 25 May 2022 — Acquisition. Regulator: SEC (Form 4). All data is openly available.
Declarations9 total
€8,1512,000 shares@ €4.07575.4% of flow
Common Stock
SEC:0001437749-22-013570:0·
Ideal exit: 19 Feb 2023 (T+270)
€16,3562,250 shares@ €7.269122.7% of flow
Common Stock
SEC:0001437749-21-027301·
Ideal exit: 15 Aug 2022 (T+270)
€16,3562,250 shares@ €7.269110.7% of flow
Common Stock
SEC:0001437749-21-027301:0·
Ideal exit: 15 Aug 2022 (T+270)
€37,8135,000 shares@ €7.562652.5% of flow
Common Stock
SEC:0001437749-21-021199·
Ideal exit: 27 May 2022 (T+270)
€37,8135,000 shares@ €7.562624.8% of flow
Common Stock
SEC:0001437749-21-021199:0·
Ideal exit: 27 May 2022 (T+270)
096,153 shares0
Common Stock
SEC:0001437749-21-020865·
096,153 shares0
Common Stock
SEC:0001437749-21-020865:0·
€17,8561,500 shares@ €11.903724.8% of flow
Common Stock
SEC:0001437749-21-014735·
Ideal exit: 11 Mar 2022 (T+270)
€17,8561,500 shares@ €11.903711.7% of flow
Common Stock
SEC:0001437749-21-014735:0·
Ideal exit: 11 Mar 2022 (T+270)
9 of 9 declarations
About Mickle Travis C
Travis C. Mickle is the President and Chief Executive Officer of KEMPHARM, INC. He is responsible for the strategic and operational leadership of the company. Mickle plays a key role in innovation and product development, thereby contributing to KEMPHARM's growth.
